Who is sponsoring NCT06217783?

NCT06217783 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT06217783?

Interventions in NCT06217783: Introcan Safety IV Catheter.

What condition does NCT06217783 study?

NCT06217783 studies Oncologic Complications and Emergencies.

Is NCT06217783 still recruiting?

NCT06217783 is currently recruiting now. Last updated 18 December 2025.

Last reviewed 2025-12-18 · How we verify

NCT06217783

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ultrasound-guided Peripheral Intravenous Catheter Placement in an Oncologic Emergency Department - a Prospective, Randomized Controlled Trial of Catheter Lengths

Recruiting now NA Last updated 18 December 2025

What this trial tests

NA trial testing Introcan Safety IV Catheter in Oncologic Complications and Emergencies in 400 participants. Currently enrolling.

Timeline

27 March 2024

Primary endpoint
1 December 2027

1 December 2027

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	400
Start date	27 March 2024
Primary completion	1 December 2027
Estimated completion	1 December 2027
Sites	1 location across United States

Drugs / interventions tested

Introcan Safety IV Catheter

Conditions studied

Oncologic Complications and Emergencies — all drugs for Oncologic Complications and Emergencies →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Oncologic Complications and Emergencies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To learn about the effects of the length of the catheter on the failure and success rate of USIV placement.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06217783 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 18 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06217783.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing